J. Spritzler

发表

Pharmacokinetics, Safety, and Antiviral Effects of Hypericin, a Derivative of St. John's Wort Plant, in Patients with Chronic Hepatitis C Virus Infection

A. Prince, L. Feinman, J. Jacobson, 2001, Antimicrobial Agents and Chemotherapy.

IL-7 administration drives T cell-cycle entry and expansion in HIV-1 infection.

M. Lederman, M. Proschan, J. Altman, 2009, Blood.

Multisite Comparison of CD4 and CD8 T-Lymphocyte Counting by Single- versus Multiple-Platform Methodologies: Evaluation of Beckman Coulter Flow-Count Fluorospheres and the tetraONE System

K. Reimann, D. Campbell, M. O'gorman, 2000, Clinical Diagnostic Laboratory Immunology.

Delayed-type hypersensitivity to recombinant HIV envelope glycoprotein (rgp160) after immunization with homologous antigen.

D. Katzenstein, T. Merigan, B. Smoller, 1999 .

Measurement of Induced Cytokines in AIDS Clinical Trials Using Whole Blood: A Preliminary Report

M. Lederman, R. Wallis, H. Lederman, 1998, Clinical Diagnostic Laboratory Immunology.

Thymic size and lymphocyte restoration in patients with human immunodeficiency virus infection after 48 weeks of zidovudine, lamivudine, and ritonavir therapy.

M. Lederman, D. Kuritzkes, J. McCune, 2000, The Journal of infectious diseases.

Measurement of Naive CD4 Cells Reliably Predicts Potential for Immune Reconstitution in HIV

G. Robbins, R. Bosch, T. Schacker, 2010, Journal of acquired immune deficiency syndromes.

Need for an External Proficiency Testing Program for Cytokines, Chemokines, and Plasma Markers of Immune Activation

R. Schooley, J. Fahey, J. Reuben, 2000, Clinical Diagnostic Laboratory Immunology.

High-dose pentoxifylline in patients with AIDS: inhibition of tumor necrosis factor production. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group.

M. Lederman, C. Flexner, B. Dezube, 1995, The Journal of infectious diseases.

infection cycle entry and expansion in HIV-1 - IL-7 administration drives T cell

M. Proschan, J. Altman, M. Fischl, 2011 .

Older HIV-infected patients on antiretroviral therapy have B-cell expansion and attenuated CD4 cell increases with immune activation reduction

M. Lederman, R. Pollard, A. Landay, 2013, AIDS.

Delayed-type hypersensitivity to recombinant HIV envelope glycoprotein (rgp160) after immunization with homologous antigen.

D. Katzenstein, T. Merigan, B. Smoller, 1999, Journal of acquired immune deficiency syndromes.

Distinct mechanisms of T cell reconstitution can be identified by estimating thymic volume in adult HIV-1 disease.

M. Lederman, R. Bosch, V. Valcour, 2005, The Journal of infectious diseases.

A Phase I, placebo-controlled trial of multi-dose recombinant human interleukin-12 in patients with HIV infection

D. Katzenstein, M. Jacobson, R. Pollard, 2002, AIDS.

M. Lederman, D. Taub, R. Pollard, 2003, The Journal of infectious diseases.

A study of the immunology, virology, and safety of prednisone in HIV-1-infected subjects with CD4 cell counts of 200 to 700 mm(-3).

M. Lederman, R. Bosch, C. Shikuma, 2003, Journal of acquired immune deficiency syndromes.

Safety, tolerability, and pharmacokinetic effects of thalidomide in patients infected with human immunodeficiency virus: AIDS Clinical Trials Group 267.

G. Kaplan, M. K. Holohan, H. Teppler, 2002, The Journal of infectious diseases.

Thalidomide for the treatment of oral aphthous ulcers in patients with human immunodeficiency virus infection. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group.

J. Fahey, J. Greenspan, D. Wohl, 1997, The New England journal of medicine.

Immunologic responses associated with 12 weeks of combination antiretroviral therapy consisting of zidovudine, lamivudine, and ritonavir: results of AIDS Clinical Trials Group Protocol 315.

M. Lederman, D. Kuritzkes, J. Leonard, 1998, The Journal of infectious diseases.

A potential role for interleukin-7 in T-cell homeostasis.

M. Lederman, S. Steinberg, J. Falloon, 2001, Blood.

Interleukin-2 Increases CD4+ lymphocyte numbers but does not enhance responses to immunization: results of A5046s.

M. Lederman, S. Kalams, R. Moss, 2003, The Journal of infectious diseases.

M. Lederman, C. Flexner, R. Pollard, 2010, AIDS research and human retroviruses.

Response to immunization with recall and neoantigens after prolonged administration of an HIV-1 protease inhibitor-containing regimen

M. Lederman, D. Kuritzkes, H. Kessler, 2000, AIDS.

Replication Capacity in Relation to Immunologic and Virologic Outcomes in HIV-1-Infected Treatment-Naive Subjects

V. Johnson, G. Robbins, D. Asmuth, 2009, Journal of acquired immune deficiency syndromes.

Incomplete reconstitution of T cell subsets on combination antiretroviral therapy in the AIDS Clinical Trials Group protocol 384.

R. Shafer, G. Robbins, D. Asmuth, 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Effect of Baseline- and Treatment-Related Factors on Immunologic Recovery After Initiation of Antiretroviral Therapy in HIV-1-Positive Subjects: Results From ACTG 384

M. Hirsch, T. Merigan, R. Shafer, 2006, Journal of acquired immune deficiency syndromes.

Evidence of immune reconstitution in antiretroviral drug-experienced patients with advanced HIV disease.

J. Phair, K. Squires, A. Landay, 2002, AIDS research and human retroviruses.

Effect of zidovudine resistance mutations on virologic response to treatment with zidovudine-lamivudine-ritonavir: genotypic analysis of human immunodeficiency virus type 1 isolates from AIDS clinical trials group protocol 315.ACTG Protocol 315 Team.

M. Lederman, D. Kuritzkes, H. Kessler, 2000, The Journal of infectious diseases.

Granulocyte-macrophage colony-stimulating factor induces modest increases in plasma human immunodeficiency virus (HIV) type 1 RNA levels and CD4+ lymphocyte counts in patients with uncontrolled HIV infection.

M. Lederman, T. Merigan, M. Jacobson, 2003, The Journal of infectious diseases.

Serum neopterin, an immune activation marker, independently predicts disease progression in advanced HIV-1 infection.

J. Fahey, D. Mildvan, S. Grossberg, 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Factors associated with viral rebound in HIV-1-infected individuals enrolled in a therapeutic HIV-1 gag vaccine trial.

M. Carrington, B. Walker, R. Schooley, 2011, The Journal of infectious diseases.

AIDS clinical trials group 5197: a placebo-controlled trial of immunization of HIV-1-infected persons with a replication-deficient adenovirus type 5 vaccine expressing the HIV-1 core protein.

R. Schooley, M. Lederman, D. Kuritzkes, 2010, The Journal of infectious diseases.

Can immune markers predict subsequent discordance between immunologic and virologic responses to antiretroviral therapy? Adult AIDS Clinical Trials Group.

D. Haas, A. Landay, D. Mildvan, 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Thalidomide for the treatment of esophageal aphthous ulcers in patients with human immunodeficiency virus infection. National Institute of Allergy and Infectious Disease AIDS Clinical Trials Group.

J. Fahey, C. Shikuma, T. Hooton, 1999, The Journal of infectious diseases.

Maximum suppression of HIV replication leads to the restoration of HIV-specific responses in early HIV disease

A. Landay, J. Spritzler, L. Al-Harthi, 2000, AIDS.

Human immunodeficiency virus type 1 activation after blood transfusion

W. O'brien, J. Spritzler, D. Georges, 1996, Transfusion.

Evaluation of TruCount Absolute-Count Tubes for Determining CD4 and CD8 Cell Numbers in Human Immunodeficiency Virus-Positive Adults

M. O'gorman, J. Spritzler, J. Nicholson, 2000, Clinical Diagnostic Laboratory Immunology.

Characteristics and Outcomes of Initial Virologic Suppressors during Analytic Treatment Interruption in a Therapeutic HIV-1 gag Vaccine Trial

M. Carrington, B. Walker, R. Schooley, 2012, PloS one.

Reanalysis of coreceptor tropism in HIV-1-infected adults using a phenotypic assay with enhanced sensitivity.

Z. Su, J. Reeves, T. Wilkin, 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Safety, Tolerability, and Immunogenicity of Repeated Doses of DermaVir, a Candidate Therapeutic HIV Vaccine, in HIV-Infected Patients Receiving Combination Antiretroviral Therapy: Results of the ACTG 5176 Trial

J. Lisziewicz, F. Lori, C. Rinaldo, 2013, Journal of acquired immune deficiency syndromes.

Effects of Mycobacterium avium complex-infection treatment on cytokine expression in human immunodeficiency virus-infected persons: results of AIDS clinical trials group protocol 853.

M. Lederman, C. Benson, M. Chernoff, 2000, The Journal of infectious diseases.

Immune reconstitution in the first year of potent antiretroviral therapy and its relationship to virologic response.

M. Lederman, D. Kuritzkes, J. Leonard, 2000, The Journal of infectious diseases.

Increases in T cell telomere length in HIV infection after antiretroviral combination therapy for HIV-1 infection implicate distinct population dynamics in CD4+ and CD8+ T cells.

M. Lederman, D. Kuritzkes, B. Levine, 1999, Clinical immunology.

Characterization of viral dynamics in human immunodeficiency virus type 1-infected patients treated with combination antiretroviral therapy: relationships to host factors, cellular restoration, and virologic end points.

M. Lederman, D. Kuritzkes, J. Leonard, 1999, The Journal of infectious diseases.

Immunophenotypic markers and antiretroviral therapy (IMART): T cell activation and maturation help predict treatment response.

D. Kuritzkes, D. Haas, R. Bosch, 2004, The Journal of infectious diseases.

A phase II, double-masked, randomized, placebo-controlled evaluation of a human monoclonal anti-Cytomegalovirus antibody (MSL-109) in combination with standard therapy versus standard therapy alone in the treatment of AIDS patients with Cytomegalovirus retinitis.

M. Hirsch, L. Hubbard, A. Caliendo, 2004, Antiviral research.

Immune reconstitution is comparable in antiretroviral-naive subjects after 1 year of successful therapy with a nucleoside reverse-transcriptase inhibitor- or protease inhibitor-containing antiretroviral regimen.

M. Lederman, D. Kuritzkes, H. Kessler, 2003, The Journal of infectious diseases.

Multiple CD4+ cell kinetic patterns and their relationships with baseline factors and virological responses in HIV type 1 patients receiving highly active antiretroviral therapy.

M. Lederman, D. Kuritzkes, H. Kessler, 2001, AIDS research and human retroviruses.

The effect of aging on T-regulatory cell frequency in HIV infection.

M. Lederman, R. Pollard, A. Landay, 2009, Clinical immunology.

HIV infection perturbs DNA content of lymphoid cells: partial correction after 'suppression' of virus replication.

M. Lederman, D. Kuritzkes, H. Kessler, 1999, AIDS.

Evidence that intermittent structured treatment interruption, but not immunization with ALVAC-HIV vCP1452, promotes host control of HIV replication: the results of AIDS Clinical Trials Group 5068.

V. Johnson, M. Saag, I. Frank, 2006, The Journal of infectious diseases.

Two-Sample Tests of Area-Under-the-Curve in the Presence of Missing Data

Victor G DeGruttola, V. DeGruttola, J. Spritzler, 2008, The international journal of biostatistics.

Placebo-controlled trial of cyclosporin-A in HIV-1 disease: implications for solid organ transplantation.

M. Lederman, D. Mildvan, R. Coombs, 2002 .

Alteration of complement protein levels after antiretroviral therapy in HIV-infected persons.

M. Lederman, D. Kuritzkes, H. Kessler, 1999, AIDS research and human retroviruses.

Thalidomide in low intermittent doses does not prevent recurrence of human immunodeficiency virus-associated aphthous ulcers.

J. Fahey, C. Shikuma, T. Hooton, 2001, The Journal of infectious diseases.

A Randomized Controlled Trial of Palifermin (Recombinant Human Keratinocyte Growth Factor) for the Treatment of Inadequate CD4+ T-Lymphocyte Recovery in Patients with HIV-1 Infection on Antiretroviral Therapy

D. Haas, J. Routy, R. Sékaly, 2014, Journal of acquired immune deficiency syndromes.

In Vitro Cell-Mediated Immune Responses of Human Immunodeficiency Virus-Infected and -Uninfected Individuals to Whole Cytomegalovirus Antigens and Their Subunits

R. Pollard, A. Landay, A. Weinberg, 2008, Clinical and Vaccine Immunology.

Pharmacokinetics and Pharmacodynamics of Thalidomide in HIV Patients Treated for Oral Aphthous Ulcers: ACTG Protocol 251

F. Aweeka, M. Chernoff, J. Jacobson, 2001 .

Placebo‐Controlled Trial of Cyclosporin‐A in HIV‐1 Disease: Implications for Solid Organ Transplantation

M. Lederman, D. Mildvan, R. Coombs, 2002, Journal of acquired immune deficiency syndromes.

Reanalysis of coreceptor tropism in HIV-1-infected adults using a phenotypic assay with enhanced sensitivity.

J. Reeves, T. Wilkin, R. Gulick, 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS A potential role for interleukin-7 in T-cell homeostasis

T. Fry, C. Mackall, D. Liewehr, 2013 .